Category: Latest News
-
Donaldson Tops Q3 Estimates, Boosts Full-Year Earnings Forecast
Donaldson Company, Inc. (NYSE:DCI), a global manufacturer of filtration solutions, delivered better-than-expected results for its fiscal third quarter on Tuesday and revised its earnings outlook upward for the full year. Still, shares edged 0.4% lower in premarket trading despite the upbeat report. The company reported adjusted earnings of $0.99 per share, exceeding Wall Street’s consensus…
-
Credo Stock Jumps Over 14% on Strong Forecast and Surging AI-Driven Revenue
Credo Technology Group Holding Ltd (NASDAQ:CRDO) saw its shares rally more than 14% in Tuesday’s premarket trading after the semiconductor company reported robust fourth-quarter earnings and issued a significantly higher-than-expected revenue forecast, fueled by booming demand in AI infrastructure. For the fiscal fourth quarter, Credo posted adjusted earnings of $0.35 per share, beating analyst projections…
-
Rio Tinto Shares Slide After Jefferies Downgrade on Strategic and Market Risks
Shares of Rio Tinto (NYSE:RIO) fell 2% in early U.S. trading Tuesday after Jefferies downgraded the mining giant from “Buy” to “Hold,” citing a more cautious outlook in light of evolving challenges and a shift in its risk-reward balance. The investment firm revised down its price targets across Rio Tinto’s global listings, cutting Rio Plc’s…
-
U.S. Stock Futures Dip as Trade Tensions and Economic Indicators Take Center Stage
U.S. equity futures slipped early Tuesday, as investors exercised caution ahead of key developments on trade policy and fresh economic data that could shape market direction in the days ahead. As of 5:40 a.m. ET, futures tied to the Dow Jones Industrial Average were down 160 points (0.4%), while S&P 500 and Nasdaq 100 futures…
-
OECD Cuts Global Growth Outlook, Highlights Tariff Impact on U.S. Economy
The Organisation for Economic Co-operation and Development (OECD) has downgraded its forecast for global economic growth, citing growing challenges posed by escalating tariffs that are hurting the U.S. economy. The OECD lowered its 2025 global GDP growth estimate to 2.9%, down from a previous forecast of 3.1%. The outlook for 2026 was also revised downward…
-
Genmab progresses with reduced dose of Rina-S in endometrial cancer studies
Genmab (NASDAQ:GMAB) has released new findings regarding its cancer therapy Rina-S, currently under investigation for endometrial cancer treatment. This development follows encouraging early results in ovarian cancer trials that prompted Genmab’s acquisition of ProfoundBio last year. Rina-S is an antibody-drug conjugate designed to target the folate receptor alpha (FRα). The latest data comes from a…
-
Citi Sees Bullish Momentum in U.S. Equities, While Global Market Signals Remain Uneven
Citigroup (NYSE:C) has highlighted a shift toward a more bullish stance in U.S. equity markets, as investor positioning across major indices strengthens. However, the outlook across global markets remains mixed, with sentiment and flows varying by region. In the U.S., the surge in investor flows has been attributed to a mix of short covering and…
-
Gold Prices Ease After Surge Driven by Geopolitical Strains and Trade Worries
Gold prices dipped during Tuesday’s Asian session, following a strong rally sparked by escalating global tensions and renewed trade concerns. The precious metal saw some profit-taking after recent gains, with markets digesting rising instability in both Eastern Europe and the Middle East. The beginning of June saw gold prices climb significantly amid fresh hostilities between…
-
U.S. Stocks Recover From Early Weakness To Close Mostly Higher
Stocks came under pressure early in the session on Monday but showed a notable turnaround over the course of the trading day. The major averages climbed well off their lows of the session and into positive territory. The major averages saw further upside going into the end of the day, reaching new highs for the…
-
Ascendis Pharma Rises as FDA Grants Priority Review for Achondroplasia Treatment
Shares of Ascendis Pharma AS (NASDAQ:ASND) rose 5.8% after the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application (NDA) for TransCon CNP under priority review. The experimental therapy targets achondroplasia, a rare genetic condition that affects bone growth in children. A Prescription Drug User Fee Act (PDUFA) decision is scheduled for…